Enveda Raises $311 Million Series E as AI Drug Discovery Startup Reaches $2 Billion Valuation

Enveda has closed a $311 million Series E round, doubling its valuation to about $2 billion as investors back its AI-led search for medicines hidden in natural chemistry. The Boulder, Colorado-based biotech said the new capital will move three oral drug candidates into later-stage development and expand PRISM, its platform for finding biologically active molecules in plants, microbes and the human body.